Michael McFarland
Optometrist · Fayetteville, ARNPI 1821228552
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,976 of the $3,419 with a category attached, or 87.0%. 21 manufacturers reported payments, led by Glaukos Corporation at 30.6% of the total. Among optometrist clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- Carl Zeiss Meditec, Inc.$512
- Carl Zeiss Meditec USA, Inc.$286
- Sight Sciences, Inc.$222
- Bausch & Lomb Americas Inc.$202
- Biotissue Holdings Inc.$196
- plus $954 from 15 others
Across 23 payments — averaging $962.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$21K
- Ivantis, Inc$800
What the payments were for
- Consulting fees$40012%
- Speaking & faculty fees$261%
- Food & beverage$2,97687%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 38 | $1,047 |
| Carl Zeiss Meditec, Inc. | 4 | $512 |
| Carl Zeiss Meditec USA, Inc. | 8 | $286 |
| Sight Sciences, Inc. | 7 | $222 |
| Bausch & Lomb Americas Inc. | 10 | $202 |
| Biotissue Holdings Inc. | 5 | $196 |
| Alcon | 5 | $144 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $127 |
| AbbVie(2 entities) | 6 | $110 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $109 |
| Oyster Point Pharma, Inc. | 4 | $77 |
| Harrow Eye, LLC | 3 | $76 |
| Amgen(2 entities) | 4 | $62 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| Rxsight Inc | 2 | $42 |
| ABB Con-cise Optical Group LLC | 1 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $33 |
| Novartis | 2 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $28 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Dompe US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,419 in reported general payments places this provider in the 95th percentile of 442 optometrist providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 41 | $22,441 |
| XiidraLifitegrast | 26 | $20,306 |
| MieboPerfluorohexyloctane/Pf | 22 | $17,920 |
| VyzultaLatanoprostene Bunod | 34 | $17,690 |
| LumiganBimatoprost | 32 | $13,905 |
| Travoprost | 30 | $4,812 |
| Prednisolone Acetate | 138 | $4,205 |
| Cyclosporine | 13 | $3,796 |
| Latanoprost | 281 | $2,441 |
| Fluorometholone | 37 | $2,176 |
| Loteprednol Etabonate | 16 | $1,872 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 101 | $1,601 |
| Bromfenac Sodium | 14 | $1,504 |
| Difluprednate | 12 | $1,162 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 100 | $1,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $202 | $55,91682 claims |
| AbbVieRestasis, Lumigan | $110 | $36,34573 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $127 | $1,87216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 optometrist providers in Arkansas.
Other optometrist in Fayetteville
- Christen CoatsFayetteville$216K
- Annie AvilezFayetteville$3K
- Benjamin LynchFayetteville$3K
- Kaitlin SpikesFayetteville$2K
- Megan BaureisFayetteville$2K
- Jennifer StaffordFayetteville$2K
- Christopher MorrisRogers$6K
- Russell SimmonsBenton$6K
- Andrea HorneTontitown$6K
- Shelby BrogdonLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.